MetLife’s price target lowered to $95 by Keefe, Bruyette & Woods, retains “Outperform” rating
**Other analyst actions: **
- Cowen reaffirms “Buy” rating (Mar 7)
- BMO initiates “Market Perform” with $97 target (Jan 23)
- JPMorgan cuts target from $88 to $86, maintains “Overweight” (Apr 2)
- Barclays lowers target to $95, keeps “Overweight” (Feb 7)
- Wells Fargo raises target to $97, rates “Overweight” (Feb 19)
** Overall consensus: Moderate Buy; average target = $92.46 **
MetLife stock rose 2.1% to $72.89 with 1M+ volume
** Key stats: **
- P/E ratio: 12.21
- PEG ratio: 0.65
- Beta: 0.89
- Debt-to-equity: 0.54
- Current & quick ratios: 0.16
- Market cap: $49.65B
- 52-week range: $65.21 – $89.05
Q4 earnings: $2.08/share (missed estimate by $0.05)
Net margin: 6.19%, ROE: 20.42%
Forecasted FY earnings: $9.65/share
Institutional ownership: 94.99%
**Hedge fund activity: **
- United Asset Strategies, Barrett & Co., Eagle Strategies, J.W. Cole, & Davis R M increased their stakes modestly in Q4
Despite strong institutional backing, analysts believe better buys may exist in the current market
https://www.marketbeat.com/instant-alerts/keefe-bruyette-woods-lowers-metlife-nysemet-price-target-to-9500-2025-04-09/